ReviewCurrent diabetes reports2019
The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus.
Review in Current diabetes reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed.
- Beneficial Effects ofCells · 2021Trial
- Trial
- Dietary fatty acid intake and gut microbiota determine circulating endocannabinoidome signaling beyond the effect of body fat.Scientific reports · 2020Trial
- Endocannabinoids and related lipids in host metabolism-gut microbiome signalling.Nature reviews. Endocrinology · 2026Review
- Longitudinal changes in endocannabinoidome and dietary lipid profile in severe obesity: impact of sleeve gastrectomy.Lipids in health and disease · 2026Article
- Exploring cannabinoid receptor CB1 autophagy and the obesity phenotype of p62-deficient mice.Biochemistry and biophysics reports · 2026Article
- The photoswitchable cannabinoid azo-HU308 enables optical control of CaFEBS open bio · 2026Article
- The Modulatory Effects ofInternational journal of endocrinology and metabolism · 2025Article
- Dietary Manganese Modulates Microbiota and Intestinal N-Acylethanolamines in a Sex-Specific Manner in Mice With Diet-Induced Obesity.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Article
- Maladaptive Peripheral Ketogenesis in Schwann Cells Mediated by CBAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Targeting the Endocannabinoidome: A Novel Approach to Managing Extraintestinal Complications in Inflammatory Bowel Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Higher plasma levels of endocannabinoids and analogues are correlated with a worse cardiometabolic profile in middle-aged adults.Journal of physiology and biochemistry · 2025Article
- Palmitoylethanolamide supplementation for human health: A state-of-the-art systematic review of Randomized Controlled Trials in patient populations.Brain, behavior, & immunity - health · 2025Review
- Review
- Pharmacology of Non-Psychoactive Phytocannabinoids and Their Potential for Treatment of Cardiometabolic Disease.Handbook of experimental pharmacology · 2025Review
- Beyond the Scale: Exploring the Endocannabinoid System's Impact on Obesity.Current diabetes reports · 2024Review
- Endocannabinoid System and Metabolism: The Influences of Sex.International journal of molecular sciences · 2024Review
- Cannabinoid Therapy in Athletics: A Review of Current Cannabis Research to Evaluate Potential Real-World Cannabinoid Applications in Sport.Sports medicine (Auckland, N.Z.) · 2024Review
- Exploring Cannabinoids with Enhanced Binding Affinity for Targeting the Expanded Endocannabinoid System: A Promising Therapeutic Strategy for Alzheimer's Disease Treatment.Pharmaceuticals (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe endocannabinoid (eCB) system, i.e. the receptors that respond to the psychoactive component of cannabis, their endogenous ligands and the ligand metabolic enzymes, is part of a larger family of lipid signals termed the endocannabinoidome (eCBome). We summarize recent discoveries of the roles that the eCBome plays within peripheral tissues in diabetes, and how it is being targeted, in an effort to develop novel therapeutics for the treatment of this increasingly prevalent disease. RECENT
findingsAs with the eCB system, many eCBome members regulate several physiological processes, including energy intake and storage, glucose and lipid metabolism and pancreatic health, which contribute to the development of type 2 diabetes (T2D). Preclinical studies increasingly support the notion that targeting the eCBome may beneficially affect T2D. The eCBome is implicated in T2D at several levels and in a variety of tissues, making this complex lipid signaling system a potential source of many potential therapeutics for the treatments for T2D.
Indexed as
Identifiers
31686231What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.